Zydus Lifesciences Gets CDSCO Panel Nod for Bioavailability Study of Antimalarial Candidate ZY-19489
Advertisement
New Delhi: The Subject Expert Committee (SEC) on Investigational New Drugs under the Central Drugs Standard Control Organisation (CDSCO) has recommended permission for Zydus Lifesciences Limited to conduct a Bioavailability study of its investigational product ZY-19489 tablet 900 mg.
The matter was taken up during the SEC meeting held on September 4, 2025, at CDSCO headquarters in New Delhi.
The company presented its proposal with Protocol No. ZY19489 1003, Version 01 dated June 17, 2025, in line with earlier recommendations made during the 04th/25th SEC (IND) meeting held on May 29, 2025.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.